Venetoclax and Decitabine in Pediatric Refractory T-cell Lymphoblastic Lymphoma.
J Pediatr Hematol Oncol
; 43(7): e991-e996, 2021 Oct 01.
Article
in En
| MEDLINE
| ID: mdl-33480649
ABSTRACT
BACKGROUND:
Overall survival of adolescents with relapsed T-cell lymphoblastic lymphoma (T-LL) remains poor with limited options for salvage therapy. The BCL-2 inhibitor venetoclax combined with hypomethylating agents like decitabine, has shown favorable responses in elderly patients with acute myeloid leukemia. OBSERVATION We present the case of a 19-year-old adolescent with stage III relapsed and refractory T-LL who did not respond to 3 lines of salvage therapy. The patient was treated with venetoclax and decitabine and achieved a dramatic response.CONCLUSION:
This case highlights the potential clinical activity of venetoclax and decitabine in relapsed T-LL.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Antineoplastic Combined Chemotherapy Protocols
/
Drug Resistance, Neoplasm
/
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Type of study:
Prognostic_studies
Limits:
Adult
/
Humans
/
Male
Language:
En
Journal:
J Pediatr Hematol Oncol
Journal subject:
HEMATOLOGIA
/
NEOPLASIAS
/
PEDIATRIA
Year:
2021
Type:
Article